Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

Abstract

BACKGROUND: Tuberous sclerosis complex is a genetic disorder affecting every organ system, but disease manifestations vary significantly among affected individuals. The diverse and varied presentations and progression can be life-threatening with significant impact on cost and quality of life. Current surveillance and management practices are highly variable among region and country, reflective of the fact that last consensus recommendations occurred in 1998 and an updated, comprehensive standard is lacking that incorporates the latest scientific evidence and current best clinical practices. METHODS: The 2012 International Tuberous Sclerosis Complex Consensus Group, comprising 79 specialists from 14 countries, was organized into 12 separate subcommittees, each led by a clinician with advanced expertise in tuberous sclerosis complex and the relevant medical subspecialty. Each subcommittee focused on a specific disease area with important clinical management implications and was charged with formulating key clinical questions to address within its focus area, reviewing relevant literature, evaluating the strength of data, and providing a recommendation accordingly. RESULTS: The updated consensus recommendations for clinical surveillance and management in tuberous sclerosis complex are summarized here. The recommendations are relevant to the entire lifespan of the patient, from infancy to adulthood, including both individuals where the diagnosis is newly made as well as individuals where the diagnosis already is established. CONCLUSIONS: The 2012 International Tuberous Sclerosis Complex Consensus Recommendations provide an evidence-based, standardized approach for optimal clinical care provided for individuals with tuberous sclerosis complex.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 58

1. 1.

   Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000;15:652-659.

   Not in our library10.1177/088307380001501003 (opens in a new tab)

2. 2.

   O’Callaghan F, Shiell A, Osborne J, Martyn C. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;352:318-319.

   Not in our library10.1016/s0140-6736(05)78872-3 (opens in a new tab)

3. 3.

   Roach E, DiMario F, Kandt R, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol. 1999;14:401-407.

   Not in our library10.1177/088307389901400610 (opens in a new tab)

4. 4.

   Roach E, Gomez M, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13:624-628.

   Not in our library10.1177/088307389801301206 (opens in a new tab)

5. 5.

   Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.

   Not in our library10.1016/0092-8674(93)90618-z (opens in a new tab)

6. 6.

   van Slegtenhorst M, deHoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805-808.

   Not in our library10.1126/science.277.5327.805 (opens in a new tab)

7. 7.

   Huang J, Dibble C, Matsuzaki M, Manning B. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28:4104-4115.

   Not in our library10.1128/mcb.00289-08 (opens in a new tab)

8. 8.
   Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease · 2011

   No notice
9. 9.

   Franz D, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2012;381:125-132.

   Not in our library10.1016/s0140-6736(12)61134-9 (opens in a new tab)

10. 10.

    Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490-498.

    Not in our library10.1002/ana.20784 (opens in a new tab)

11. 11.

    Krueger DA, Care MM, Holland K, et al. Everolimus for sub-ependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-1811.

    Not in our library10.1056/nejmoa1001671 (opens in a new tab)

12. 12.

    Bissler J, Kingswood J. Renal angiomyolipomata. Kidney Int. 2004;66:924-934.

    Not in our library10.1111/j.1523-1755.2004.00838.x (opens in a new tab)

13. 13.

    Davies DM, De Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangio-leiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071-4081.

    Not in our library10.1158/1078-0432.ccr-11-0445 (opens in a new tab)

14. 14.

    Bissler J, McCormack F, Young L, et al. Sirolimus for angiomyolipomata in tuberous sclerosis or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140-151.

    Not in our library10.1056/nejmoa063564 (opens in a new tab)

15. 15.

    McCormack F, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595-1606.

    Not in our library10.1056/nejmoa1100391 (opens in a new tab)

16. 16.

    Northrup H, Krueger D. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49:243-254.

    Not in our library10.1016/j.pediatrneurol.2013.08.001 (opens in a new tab)

17. 17.

    NCCN Guidelines® and Derivative Information Products: User Guide. 2012.

    Not in our library

18. 18.

    Inoue Y, Nemoto Y, Murata R, et al. CT and MR imaging of cerebral tuberous sclerosis. Brain Dev. 1998;20:209-221.

    Not in our library10.1016/s0387-7604(98)00022-9 (opens in a new tab)

19. 19.

    Kalantari B, Salamon N. Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging. AJR Am J Roentgenol. 2008;190:W304-W309.

    Not in our library10.2214/ajr.07.2928 (opens in a new tab)

20. 20.

    Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657-668.

    Not in our library10.1016/s0140-6736(08)61279-9 (opens in a new tab)

21. 21.

    Thiele EA. Managing epilepsy in tuberous sclerosis complex. J Child Neurol. 2004;19:680-686.

    Not in our library10.1177/08830738040190090801 (opens in a new tab)

22. 22.

    de Vries P, Kwiatkowsi DJ, Whittemore VH, Thiele EA. Neurodevelopmental, psychiatric and cognitive aspects of tuberous sclerosis complex. Tuberous Sclerosis Complex. 2010;229-268.

    Not in our library

23. 23.

    Halpenny D, Snow A, McNeill G, Torreggiani W. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clin Radiol. 2010;65:99-108.

    Not in our library10.1016/j.crad.2009.09.014 (opens in a new tab)

24. 24.

    Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.

    Not in our library10.7326/0003-4819-130-6-199903160-00002 (opens in a new tab)

25. 25.

    Levey A, Stevens L, Schmid C, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.

    Not in our library10.7326/0003-4819-150-9-200905050-00006 (opens in a new tab)

26. 26.

    Schwartz G, Munoz A, Schneider M, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629-637.

    Not in our library10.1681/asn.2008030287 (opens in a new tab)

27. 27.

    Nehus E, Laskin B, Kathman T, Bissler J. Performance of cystatin C-based equations in a pediatric cohort at high risk of kidney injury. Pediatr Nephrol. 2013;28:453-461.

    Not in our library10.1007/s00467-012-2341-3 (opens in a new tab)

28. 28.

    Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008;358:199-200.

    Not in our library10.1056/nejmc0707517 (opens in a new tab)

29. 29.

    Young LR, VanDyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangio-leiomyomatosis from other diseases. Chest. 2010;138:674-681.

    Not in our library10.1378/chest.10-0573 (opens in a new tab)

30. 30.

    Krueger D, Franz D. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008;10:299-313.

    Not in our library10.2165/00148581-200810050-00004 (opens in a new tab)

31. 31.

    Moavero R, Pinci M, Bombardieri R, Curatolo P. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician’s perspective. Childs Nerv Syst. 2011;27:1203-1210.

    Not in our library10.1007/s00381-011-1406-0 (opens in a new tab)

32. 32.

    Berhouma M. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon’s perspective. World J Pediatr. 2010;6:103-110.

    Not in our library10.1007/s12519-010-0025-2 (opens in a new tab)

33. 33.

    De Ribaupierre S, Dorfmüller G, Bulteau C, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60:83-89.

    Not in our library10.1227/01.neu.0000249216.19591.5d (opens in a new tab)

34. 34.

    Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14:146-149.

    Not in our library10.1016/j.ejpn.2009.03.003 (opens in a new tab)

35. 35.

    Camposano S, Major P, Halpern E, Thiele E. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49:1186-1191.

    Not in our library10.1111/j.1528-1167.2008.01589.x (opens in a new tab)

36. 36.

    JóŸwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011;15:424-431.

    Not in our library10.1016/j.ejpn.2011.03.010 (opens in a new tab)

37. 37.

    Parisi P, Bombardieri R, Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol. 2007;11:331-336.

    Not in our library10.1016/j.ejpn.2007.03.010 (opens in a new tab)

38. 38.

    Curatolo P, JóŸwiak S, Nabbout R. TSC Consensus Meeting for SEGA and Epilepsy Management. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2012;16:582-586.

    Not in our library10.1016/j.ejpn.2012.05.004 (opens in a new tab)

39. 39.

    Chu-Shore C, Major P, Camposano S, Muzykewicz D, Thiele E. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51:1236-1241.

    Not in our library10.1111/j.1528-1167.2009.02474.x (opens in a new tab)

40. 40.

    Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817-824.

    Not in our library10.1016/s0140-6736(12)61767-x (opens in a new tab)

41. 41.

    The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555-576.

    Not in our library

42. 42.

    Jimenez RE, Eble JN, Reuter VE, et al. Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol. 2001;14:157-163.

    Not in our library10.1038/modpathol.3880275 (opens in a new tab)

43. 43.

    Henske E. The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked? Curr Mol Med. 2004;4:825-831.

    Not in our library10.2174/1566524043359610 (opens in a new tab)

44. 44.

    Lemaitre L, Claudon M, Dubrulle F, Mazeman E. Imaging of angiomyolipomas. Semin Ultrasound CT MR. 1997;18:100-114.

    Not in our library10.1016/s0887-2171(97)90054-8 (opens in a new tab)

45. 45.

    Bissler JJ, Racadio J, Donnelly LF, Johnson ND. Reduction of post-embolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis. 2002;39:966-971.

    Not in our library10.1053/ajkd.2002.32770 (opens in a new tab)

46. 46.

    Mourikis D, Chatziioannou A, Antoniou A, Kehagias D, Gikas D, Vlahos L. Selective arterial embolization in the management of symptomatic renal angiomyolipomas. Eur J Radiol. 1999;32:153-159.

    Not in our library10.1016/s0720-048x(98)00179-x (opens in a new tab)

47. 47.

    Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081.

    Not in our library10.1016/s0140-6736(10)60674-5 (opens in a new tab)

48. 48.

    Patel U, Simpson E, Kingswood JC, Saggar-Malik AK. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. Clin Radiol. 2005;60:665-673.

    Not in our library10.1016/j.crad.2005.01.009 (opens in a new tab)

49. 49.

    Haemel A, O’Brian A, Teng J. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715-718.

    Not in our library10.1001/archdermatol.2010.125 (opens in a new tab)

50. 50.

    Koenig M, Hebert A, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topical applied rapamycin. Drugs R D. 2012;12:121-126.

    Not in our library10.2165/11634580-000000000-00000 (opens in a new tab)

51. 51.

    Papadavid E, Markey A, Bellaney G, Walker NPJ. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol. 2002;147:337-342.

    Not in our library10.1046/j.1365-2133.2002.04968.x (opens in a new tab)

52. 52.

    Weinberger CH, Endrizzi B, Hook KP, Lee PK. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser. Dermatol Surg. 2009;35:1849-1851.

    Not in our library10.1111/j.1524-4725.2009.01304.x (opens in a new tab)

53. 53.

    Weiss ET, Geronemus RG. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med. 2010;42:357-360.

    Not in our library10.1002/lsm.20939 (opens in a new tab)

54. 54.

    Damm DD, Tomich CE, White DK, Drummond JF. Intraosseous fibrous lesions of the jaws: a manifestation of tuberous sclerosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:334-340.

    Not in our library10.1016/s1079-2104(99)70219-2 (opens in a new tab)

55. 55.

    Mlynarczyk G. Enamel pitting: a common symptom of tuberous sclerosis. Oral Surg Oral Med Oral Pathol. 1991;71:63-67.

    Not in our library10.1016/0030-4220(91)90523-f (opens in a new tab)

56. 56.

    Franz D. Non-neurologic manifestations of tuberous sclerosis complex. J Child Neurol. 2004;19:690-698.

    Not in our library10.1177/08830738040190091001 (opens in a new tab)

57. 57.

    Sparling J, Hong C, Brahim J, Moss J, Darling T. Oral findings in 58 adults with tuberous sclerosis complex. J Am Acad Dermatol. 2007;56:786-790.

    Not in our library10.1016/j.jaad.2006.11.019 (opens in a new tab)

58. 58.

    Greiner HM, Lynch ER, Fordyce S, et al. Vigabatrin for childhood partial-onset epilepsies. Pediatr Neurol. 2012;46:83-88.

    Not in our library10.1016/j.pediatrneurol.2011.11.020 (opens in a new tab)

Cited by papers we hold 9

• Validation of the self-report quantified Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Checklist (TAND-SQ) · 2025
  Not checked
• Genetic Testing in Neurodevelopmental Disorders · 2021
  No notice
• Renal angiomyolipomatosis and bleeding aneurysms in a tuberous sclerosis context: selective artery embolization in a girl with end-stage renal failure · 2020
  Not checked
• The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1 · 2020
  Not checked
• TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study · 2018
  No notice
• TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients · 2017
  No notice
• The genomic landscape of tuberous sclerosis complex · 2017
  No notice
• Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study · 2016
  No notice
• Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy · 2015
  Not checked

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.